This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EYES Second Sight Medical Products (EYES) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Second Sight Medical Products Stock (NASDAQ:EYES) 30 days 90 days 365 days Advanced Chart Get EYES alerts:Sign Up Key Stats Today's Range N/A50-Day Range$4.11▼$13.0552-Week Range N/AVolume36,800 shsAverage Volume132,982 shsMarket Capitalization$54.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California. Read More Receive EYES Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter. Email Address EYES Stock News HeadlinesStartups Like Science and Musk's Neuralink Aim to Help Blind People SeeNovember 13, 2024 | msn.comEye drops claiming to change eye color raise alarm among eye specialists on TikTokNovember 12, 2024 | msn.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 16 at 2:00 AM | Porter & Company (Ad)I Tried PRFM Injections, the Ultimate Undereye Filler AlternativeNovember 9, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Vivani Medical (VANI) with Buy RecommendationNovember 7, 2024 | msn.comDoes Guy Win The Golden Bachelorette? Joan Hinted at Where They Stand NowNovember 6, 2024 | msn.comOprah Winfrey Issues Stark Warning to Those Planning Not to VoteNovember 5, 2024 | msn.comQ3 2024 GeneDx Holdings Corp Earnings CallOctober 31, 2024 | finance.yahoo.comSee More Headlines EYES Stock Analysis - Frequently Asked Questions How were Second Sight Medical Products' earnings last quarter? Second Sight Medical Products, Inc. (NASDAQ:EYES) released its quarterly earnings results on Monday, June, 29th. The medical device company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $0.48. When did Second Sight Medical Products' stock split? Shares of Second Sight Medical Products reverse split on the morning of Friday, August 19th 2022.The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Second Sight Medical Products IPO? Second Sight Medical Products (EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO. What other stocks do shareholders of Second Sight Medical Products own? Based on aggregate information from My MarketBeat watchlists, some other companies that Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Shopify (SHOP). Company Calendar Last Earnings6/29/2020Today8/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:EYES CIK1266806 Webwww.secondsight.com Phone(818) 833-5000Fax818-833-5067Employees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-13.58% Return on Assets-13.02% Debt Debt-to-Equity RatioN/A Current Ratio22.15 Quick Ratio22.15 Sales & Book Value Annual Sales$3.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / BookN/AMiscellaneous Outstanding Shares13,135,000Free Float6,935,000Market Cap$54.38 million OptionableOptionable Beta2.55 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:EYES) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Second Sight Medical Products, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Second Sight Medical Products With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.